Organon & Co.
OGN
Rank in Stocks
#4350
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Share Price
$13.76
Last synced: 2026-10-16
Market Cap
$3.61B
Change (1 day)
-0.04%
Change (1 year)
48.28%
Country
US
Trade Organon & Co. (OGN)
Category
Healthcare
EPS for Organon & Co. (OGN)
EPS as of June 2026 TTM: $0.79
According to Organon & Co. latest financial reports and stock price the company's current EPS (TTM) is $0.79. At the end of 2024 the company had a EPS of $3.36 a decrease compared to its 2023 EPS that were of $4.01.
EPS history for Organon & Co. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.79 | 9.72% |
| 2025 | $0.72 | -78.57% |
| 2024 | $3.36 | -16.21% |
| 2023 | $4.01 | 11.08% |
| 2022 | $3.61 | -32.27% |
| 2021 | $5.33 | -37.44% |
| 2020 | $8.52 | -32.97% |
| 2019 | $12.71 | 49.35% |
| 2018 | $8.51 | 19.69% |
| 2017 | $7.11 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $29.89 | 3,683.54% |
US
|
|
| $6.60 | 735.44% |
US
|
|
| $3.55 | 349.37% |
US
|
|
| $20.39 | 2,480.89% |
CH
|
|
| $1.26 | 59.49% |
US
|
